3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof
AssigneeShanghai Leado Pharmatech Co. Ltd.
InventorsYouxin WANG, Zhenlin QU, Lingling ZHANG
Life of this patent
Estimating the term…
Abstract
Disclosed are a 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof. Specifically disclosed is a compound or a pharmacologically acceptable salt thereof or a prodrug thereof. The compound has the structure of formula I. The compound or the pharmacologically acceptable salt thereof or the prodrug thereof has excellent inhibition to transient receptor potential (TPR) channel proteins, and has good therapeutic effect on diseases related to the TPR channel proteins.
Claims21
-22. (canceled)
A method for (a) inhibiting a transient receptor potential channel protein (TRPA1);
- or (b) preventing and/or treating a disease related to transient receptor potential channel protein (TRPA1);
- which comprises administering a compound, or a pharmaceutically acceptable salt, or a prodrug thereof to a subject in need;
- wherein the compound has a structure of formula Z:
- wherein,
- ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
- R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- X is an oxygen atom, sulfur atom or nitrogen atom;
- R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- n is 1, 2 or 3;
- “*” means that the configuration of the compound is racemate;
- wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
- wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.
A method for (a) inhibiting transient receptor potential channel protein (TRP);
- or (b) preventing and/or treating a disease related to transient receptor potential channel protein (TRP);
- which comprises administering a compound, or a pharmaceutically acceptable salt, or a prodrug thereof to a subject in need;
- wherein the compound has a structure of formula I:
- wherein,
- ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, o a substituted or unsubstituted 5-7 membered heteroaromatic ring;
- R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- X is an oxygen atom, sulfur atom or nitrogen atom;
- R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- n is 1, 2 or 3;
- wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
- wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.
A compound, or a pharmaceutically acceptable salt, or a prodrug thereof, wherein the compound has a structure of formula Z:
- wherein,
- ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
- R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- X is an oxygen atom, sulfur atom or nitrogen atom;
- R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- n is 1, 2 or 3;
- “*” means that the configuration of the compound is racemate;
- wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
- wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.
A compound, or a pharmaceutically acceptable salt, or a prodrug there of, wherein the compound has a structure of formula I:
- wherein,
- ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring, a substituted or unsubstituted 5-7 membered heterocyclic ring, or a substituted or unsubstituted 5-7 membered heteroaromatic ring;
- R1 and R2 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- X is an oxygen atom, sulfur atom or nitrogen atom;
- R3 is hydrogen, halogen, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C3-C7 cycloalkyl;
- n is 1, 2 or 3;
- wherein any of the “substituted” means that 1-4 (preferably 1, 2, 3, or 4) hydrogen atoms on the group are each independently substituted by a substituent selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C1-C3 haloalkyl, halogen, nitro, cyano, hydroxyl, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 haloalkoxy, benzyl, 6-membered aryl or 5- or 6-membered heteroaryl (preferably C5 heteroaryl);
- wherein the heterocyclic ring, heteroaromatic ring and heteroaryl each independently have 1 to 3 (preferably 1, 2 or 3) heteroatoms selected from N, O and S.
Dependencies are inferred from the claim text.